Inozyme Pharma Inc (INZY) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access INZY Annual Balance Sheets →
The balance sheet figures below highlight longer-term patterns in how Inozyme Pharma Inc finances operations and invests in assets.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2025)
(Dec 31 2024) (Sep 30 2024) (Jun 30 2024) (Mar 31 2024)
Assets
Cash & cash equivalent25.85
Short-term Investments, Total58.93
Cash & Short-term Investments83.00
Other Current Assets0.31
Prepaid Expense And Other Assets Current8.55
Total Current Assets93.64
Equipment/Property/Plant Net0.61
Prepaid Expense, Noncurrent, Total PR0.51
Other Assets, Noncurrent0.41
Restricted Cash0.31
Restricted Cash Noncurrent-
Total Assets95.16
Liabilities
Accounts Payable, Current AC3.67
Accrued Liabilities, Current AC12.74
Other Liabilities, Current26.37
Total Current Liabilities42.78
Long-term debt20.59
Other Long-term Debt, Current OT0.00
Total Long-term Debt20.59
Other liabilities, Noncurrent0.00
OperatingLeaseLiabilityNoncurrent-
Operating Lease Liability Current0.67
Total Liabilities63.37
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock447.79
Retained Earnings / Accumulated Deficit-415.99
Other Equity-0.01
Common Stockholder's Equity31.80
Total Stockholder's Equity31.80
Liabilities & Stockholder's Equity95.16
4 historic quarters locked

Sign in to unlock the full Inozyme Pharma Inc balance sheet history.

About Inozyme Pharma Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-25-070921

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.